Merck & Co., Inc. (LON:0QAH)
London flag London · Delayed Price · Currency is GBP · Price in USD
79.20
-0.86 (-1.07%)
At close: Jul 21, 2025

Merck & Co. Company Description

Merck & Co., Inc. operates as a healthcare company worldwide.

It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.

It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands.

The company has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors.

Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Merck & Co., Inc.
CountryUnited States
Founded1891
IndustryDrug Manufacturers - General
SectorHealthcare
Employees75,000
CEORobert Davis

Contact Details

Address:
126 East Lincoln Avenue
Rahway, New Jersey 07065
United States
Phone908 740 4000
Websitemerck.com

Stock Details

Ticker Symbol0QAH
ExchangeLondon Stock Exchange
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberUS58933Y1055
SIC Code2834

Key Executives

NamePosition
Robert M. Davis J.D.Chairman, President and Chief Executive Officer
Betty D. LarsonExecutive Vice President and Chief Human Resources Officer
Richard R. DeLuca Jr.Executive Vice President and President of Merck Animal Health
Dr. Dean Y. Li M.D., Ph.D.Executive Vice President and President of Merck Research Laboratories
Dalton E. Smart IIISenior Vice President of Finance, Principal Accounting Officer and Global Controller
David Michael WilliamsExecutive Vice President and Chief Information and Digital Officer
Peter DannenbaumVice President of Investor Relations
Jennifer L. Zachary J.D.Executive Vice President and General Counsel
Cristal N. DowningExecutive Vice President and Chief Communications and Public Affairs Officer
Sanat ChattopadhyayExecutive Vice President and President of Merck Manufacturing Division